Enterprise Value

1.111B

Cash

351.4M

Avg Qtr Burn

-25.72M

Short % of Float

3.69%

Insider Ownership

7.78%

Institutional Own.

86.49%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
KER-050 Details
Blood disorder, Cancer, Myelodysplastic syndrome

Phase 2

Data readout

KER-050 Details
Lung disease, Myelofibrosis

Phase 2

Data readout

KER-047 (ALK2 inhibitor) Details
Fibrodysplasia ossificans progressiva, Anemia

Phase 2

Data readout

KER-047 (ALK2 inhibitor) Details
Myelodysplastic syndrome, Myelofibrosis

Phase 2

Data readout

KER-012 Details
Pulmonary hypertension, Cardiovascular disease

Phase 2

Initiation